Evolus Inc
For the period ended Dec 31, 2024. Filed Mar 4, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 4, 2025
EOLS$6.81-2.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
(in thousands)
| Year Ended December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Cash flows from operating activities | |||
| Net loss | $(50,420) | $(61,685) | $(74,412) |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Depreciation and amortization | 5,297 | 5,133 | 3,722 |
| Stock-based compensation | 22,254 | 16,458 | 10,833 |
| Provision for bad debts | 2,449 | 1,440 | 1,598 |
| Amortization of operating lease right-of-use assets | 723 | 734 | 775 |
| Amortization of debt discount and issuance costs | 1,147 | 1,116 | 1,086 |
| Deferred income taxes | (21) | 5 | (18) |
| Revaluation of contingent royalty obligation to Evolus Founders | 7,176 | 4,257 | 5,755 |
| Non-cash in-process research and development expense | — | 4,429 | — |
| Changes in assets and liabilities: | |||
| Inventories | 3,252 | 4,193 | (10,688) |
| Accounts receivable | (19,602) | (9,521) | (9,389) |
| Prepaid expenses | 2,351 | (1,798) | 1,180 |
| Other assets | 706 | (864) | 4,854 |
| Accounts payable | 391 | (1,017) | 968 |
| Accrued expenses | 7,014 | 9,019 | (5,199) |
| Accrued litigation settlement | — | (5,000) | (15,000) |
| Operating lease liabilities | (716) | (907) | (977) |
| Net cash used in operating activities | (17,999) | (34,008) | (84,912) |
| Cash flows from investing activities | |||
| Purchases of property and equipment | (1,472) | (473) | (1,618) |
| Additions to capitalized software | (3,351) | (1,154) | (1,321) |
| Net cash used in investing activities | (4,823) | (1,627) | (2,939) |
| Cash flows from financing activities | |||
| Payment of contingent royalty obligation to Evolus Founders | (7,441) | (5,537) | (4,185) |
| Proceeds from issuance of long-term debt, net of discounts | — | 50,000 | — |
| Payments for debt issuance costs | — | (46) | (500) |
| Proceeds from follow-on offering, net of underwriting fees | 51,211 | — | — |
| Payments for offering costs | (248) | — | — |
| Cash proceeds from exercise of stock options | 4,882 | 231 | 539 |
| Tax withholding paid on behalf of employees for net share settlement | (990) | (7) | — |
| Net cash provided by (used in) financing activities | 47,414 | 44,641 | (4,146) |
| Effect of exchange rates on cash and cash equivalents | (478) | (90) | (337) |
| Change in cash and cash equivalents | 24,114 | 8,916 | (92,334) |
| Cash and cash equivalents, beginning of period | 62,838 | 53,922 | 146,256 |
| Cash and cash equivalents, end of period | $86,952 | $62,838 | $53,922 |
(in thousands)
| Year Ended December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Supplemental disclosure of cash flow information | |||
| Cash paid for interest | $17,545 | $12,708 | $7,999 |
| Cash paid for income taxes | 235 | 117 | 76 |
| Non-cash investing and financing information | |||
| Operating lease right-of-use assets obtained in exchange for operating lease liabilities | 3,002 | 4,550 | — |
| Issuance of common stock in connection with Symatese Europe Agreement | — | 1,476 | — |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.